3/3
06:30 am
imux
Immunic to Participate in Investor Conferences in March
Low
Report
Immunic to Participate in Investor Conferences in March
3/2
08:03 am
imux
Immunic (IMUX) had its price target lowered by HC Wainwright from $8.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Immunic (IMUX) had its price target lowered by HC Wainwright from $8.00 to $5.00. They now have a "buy" rating on the stock.
2/28
03:14 pm
imux
Immunic secures $400M to support late-stage MS trials - ICYMI [Yahoo! Finance]
Low
Report
Immunic secures $400M to support late-stage MS trials - ICYMI [Yahoo! Finance]
2/26
09:20 am
imux
Immunic sets stage for phase 3 MS data readout after $400M financing [Yahoo! Finance]
Low
Report
Immunic sets stage for phase 3 MS data readout after $400M financing [Yahoo! Finance]
2/26
06:39 am
imux
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/26
06:30 am
imux
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
Medium
Report
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
2/17
04:53 pm
imux
Immunic closes $200M private placement to fund late-stage MS trials [Yahoo! Finance]
Low
Report
Immunic closes $200M private placement to fund late-stage MS trials [Yahoo! Finance]
2/17
04:05 pm
imux
Immunic Announces Closing of Oversubscribed Private Placement Financing
Low
Report
Immunic Announces Closing of Oversubscribed Private Placement Financing
2/16
05:53 am
imux
Immunic secures $400m fund to support commercial-stage development [Yahoo! Finance]
Low
Report
Immunic secures $400m fund to support commercial-stage development [Yahoo! Finance]
2/14
07:51 pm
imux
Why Immunic (IMUX) Is Up 47.2% After $400 Million MS Push And Leadership Shake-Up [Yahoo! Finance]
Low
Report
Why Immunic (IMUX) Is Up 47.2% After $400 Million MS Push And Leadership Shake-Up [Yahoo! Finance]
2/13
11:33 pm
imux
Biotech Breakout: This Microcap Locks In Up to $400 Million to Fuel Late-Stage Push [Globe and Mail, The (Toronto, Canada)]
Low
Report
Biotech Breakout: This Microcap Locks In Up to $400 Million to Fuel Late-Stage Push [Globe and Mail, The (Toronto, Canada)]
2/13
03:01 pm
imux
Update: Immunic Prices Private Placement, to Seek New CEO; Shares Surge [Yahoo! Finance]
Medium
Report
Update: Immunic Prices Private Placement, to Seek New CEO; Shares Surge [Yahoo! Finance]
2/13
11:44 am
imux
Immunic shares gain on $400M raise to fund late-stage MS trials, commercial push [Yahoo! Finance]
High
Report
Immunic shares gain on $400M raise to fund late-stage MS trials, commercial push [Yahoo! Finance]
2/13
08:25 am
imux
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at D. Boral Capital from $8.00 to $4.00. They now have a "buy" rating on the stock.
High
Report
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at D. Boral Capital from $8.00 to $4.00. They now have a "buy" rating on the stock.
2/13
06:30 am
imux
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
High
Report
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
2/9
08:04 am
imux
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
High
Report
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
2/6
05:33 pm
imux
Immunic (NASDAQ:IMUX) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
High
Report
Immunic (NASDAQ:IMUX) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
2/5
06:10 am
imux
Immunic (NASDAQ:IMUX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Medium
Report
Immunic (NASDAQ:IMUX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
2/4
07:22 am
imux
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis [Yahoo! Finance]
Medium
Report
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis [Yahoo! Finance]
2/4
06:30 am
imux
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Medium
Report
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
1/12
04:40 am
imux
Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10% [Yahoo! Finance]
Medium
Report
Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10% [Yahoo! Finance]
1/7
09:24 am
imux
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $8.00 price target on the stock.
Medium
Report
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $8.00 price target on the stock.
1/7
07:22 am
imux
Immunic Highlights 2025 Accomplishments and Upcoming Milestones [Yahoo! Finance]
Medium
Report
Immunic Highlights 2025 Accomplishments and Upcoming Milestones [Yahoo! Finance]
1/7
06:30 am
imux
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Medium
Report
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
12/16
04:37 pm
imux
Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.